Effectors of Hyperlipidemia Among Patients with HIV/AIDS Taking Second-line Antiretroviral Therapy Based on Registry Data

Abstract

Objective: In this study, we aimed to determine the prevalence and effectors of hyperlipidemia among people living with HIV/AIDS (PLWHA) and taking second-line antiretroviral therapy (ART) using registry data in central China. Methods: We conducted a cross-sectional study and collected information of PLWHA on second-line ART during 2018 from two medical registries. Hyperlipidemia was defined according to the 2016 Chinese guidelines for the management of dyslipidemia in adults. Univariate and multivariate logistic regression analyses were performed to explore the influencing factors of hyperlipidemia. We calculated odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 2886 PLWHA taking second-line ART were included in this study, and 978 (33.9%) had hyperlipidemia. Female patients, those with hyperglycemia, and patients with CD4+ cell counts >500 cells/μL had a higher prevalence of hyperlipidemia with 37.0%, 49.0%, and 41.3%, respectively. Multivariate analysis showed that CD4+ cell count 350–500 cells/μL (OR=1.72, 95% CI: 1.26–2.38), CD4+ cell count >500 cells/μL (OR=2.49, 95% CI: 1.85–3.38), and FPG >6.2 mmol/L (OR=2.08, 95% CI:1.64–2.65) were risk factors for hyperlipidemia. Male sex (OR=0.72, 95% CI: 0.61–0.85) and Hb <110 g/L (OR=0.59, 95% CI: 0.45–0.76) were protective factors against hyperlipidemia. Conclusions: PLWHA on second-line ART had a higher prevalence of hyperlipidemia. Gender, CD4+ cell count, FPG, and hemoglobin were influencing factors of hyperlipidemia.